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Objective. To identify candidate microRNAs (miRNAs) that potentially regulate the initiation and progression of osteoarthritis (OA).
Methods. OA was induced in 10-12-week-old male wild-type C57BL/6 mice and in mice resistant to aggrecanase cleavage (Acan p.374ALGS?374NVYS) by destabilization of the medial meniscus (DMM). Pathologic changes of OA were scored histologically. RNA from cartilage and subchondral bone was harvested in parallel by laser microdissection at 1 week and 6 weeks postsurgery. Global miRNA expression profiling was performed using Agilent microarrays and was validated by quantitative polymerase chain reaction analysis.
Results. Wild-type DMM mice had characteristic cartilage degeneration, subchondral bone sclerosis, and osteophyte formation. While no miRNA dysregulation was seen in subchondral bone, 139 miRNAs were differentially expressed in cartilage obtained at 1 and/or 6 weeks after OA initiation from wild-type mice that underwent DMM. To prioritize OA candidates, dysregulated miRNAs with human orthologs were filtered, and paired miRNA/messenger RNA (mRNA) expression analysis was conducted to identify those with corresponding changes in mRNA target transcripts in the DMM mouse cartilage. An important cohort also overlapped with miRNAs identified in human end-stage OA. Comparisons of miRNA dysregulation in DMM mouse cartilage where aggrecan cleavage was genetically ablated demonstrated that all candidates were independent of aggrecan breakdown, earmarking these as important to the critical stages of OA initiation. Furthermore, functional enrichment analysis and data annotation revealed the responses to mechanical stimuli, apoptotic processes, and core extracellular matrix structural and regulatory factors to be potentially influenced by OA-dysregulated miRNA/mRNA networks.
Conclusion. Our comprehensive analyses identified high-priority miRNA candidates that have potential as biomarkers and therapeutic targets in human OA.
Although many osteoarthritis (OA)-related molecular pathways have been described, the key triggering molecular events remain elusive. As a result, there are currently no registered therapies that halt disease onset or progression (1, 2) . Discovering key pathologic pathways that may offer new targets for disease-modifying therapies is a priority.
Articular cartilage degeneration, the characteristic feature of OA, is accompanied by sclerosis of the underlying subchondral bone (SCB), synovitis, osteophyte formation, and ligament and meniscal damage, ultimately resulting in complete joint "organ" failure (3). It is clear that all joint tissues can contribute to the pathologic process, with the regulatory interplay between cartilage and SCB of importance (4, 5) . However, the molecular characteristics of the disease pathways both within and between cartilage and SCB remains poorly characterized, which highlights the critical need for parallel studies on both of these tissues during OA initiation and progression.
MicroRNAs (miRNAs) are a family of evolutionarily conserved small noncoding RNAs that posttranscriptionally modulate gene expression (6) . To date, more than 2,500 mature miRNAs have been identified in humans (see ref. 7 and online at http://www.mirbase.org/). Mature miRNAs (21-25 nucleotides) are formed from larger precursor miRNAs that are processed by RNase III Drosha-DGCR8 complex and, subsequently, Dicer to liberate mature miRNAs that associate with Argonaute proteins in an RNA-induced silencing complex (RISC). RISC-effector complexes are guided to target genes, where basepairing of the miRNA results in translational repression or messenger RNA (mRNA) decay of the target transcript.
Cartilage-specific ablation of Dicer was shown to result in skeletal abnormalities, decreased chondrocyte proliferation, and accelerated hypertrophic differentiation in mice with Dicer gene deletion (8) . Moreover, early postnatal deletion of Drosha in articular chondrocytes resulted in increased cell death and decreased matrix proteoglycan content (9) . These studies demonstrate the critical role of miRNAs in cartilage development and health. An increasing number of specific miRNAs have also been suggested as regulators of chondrocyte-driven processes central to OA pathology (for review, see refs. 10 and 11), making miRNAs potential new candidates for mechanistically based therapies and clinical biomarkers.
In the present study, we explored the expression of miRNAs in articular cartilage and SCB in a mouse model of OA in which the disease was surgically induced by destabilization of the medial meniscus (DMM). This model of posttraumatic OA not only provides information about OA pathogenesis in general (12, 13) , but it also allows the molecular interrogation of the early stages of disease that is not possible with tissues from OA patients. Studying early disease stages is pivotal, as it represents a critical time for maximizing therapeutic benefit and improving patient outcomes. Furthermore, by comparing miRNA candidates in wildtype mice and mice in which aggrecan breakdown was genetically ablated, we were able to identify miRNA dysregulation that was independent or upstream of aggrecan breakdown, which provided insights into the earliest molecular events in OA cartilage degradation. Our study is the first to demonstrate that dysregulation of miRNAs in OA is tissue-specific, with significant changes restricted to cartilage and independent of aggrecanolysis. These findings validated OA candidate miRNAs previously identified in human end-stage OA and identified miRNAs not hitherto associated with OA that may be novel therapeutic targets.
MATERIALS AND METHODS
Animal models and OA induction. OA was surgically induced in 10-12-week-old male wild-type C57BL/6 mice and Jaffa mice, which are resistant to aggrecanase cleavage (Acan p.374ALGS?374NVYS) (14) , by bilateral DMM (15) (16) (17) . As controls, bilateral sham-operations were performed, in which the medial meniscotibial ligament was visualized but not transected. All procedures were approved by the Animal Ethics Committee of the Royal North Shore Hospital (protocol RESP/14/77).
Mice were randomly allocated to treatment groups/harvest time points, were maintained under standardized conditions (18) , and were euthanized at 1 week or 6 weeks postsurgery. For each animal, one knee joint was processed for histology and the other was used for microarray expression/quantitative polymerase chain reaction (qPCR) analysis. Microarray experiments on cartilage samples were performed on 3 mice per group per time point, each consisting of RNA pooled from 3 mice. Validation by qPCR was performed on the same 3 pooled RNA samples and 4 additional biologic replicates per group per time point. Microarray experiments on SCB samples were performed on 4 mice per group per time point.
Histopathologic analysis of OA features. Knee joints were fixed and then decalcified, and serial sagittal sections across the medial femorotibial joint were prepared and stained with toluidine blue-fast green (16, 17) . Cumulative scores (total of the scores for all sections) for histopathologic features of OA in cartilage and SCB were determined by 2 independent observers (VR and CBL) who were blinded with regard to the experimental group. A single histologic score was calculated from the mean of the scores for the following features in each mouse: cartilage proteoglycan loss, structural damage, chondrocyte hypertrophy, SCB sclerosis, and osteophyte size and maturity.
Microarray expression profiling of cartilage and SCB. Joint dissection, laser microdissection, RNA extraction, and quality assurance were performed as described previously (19, 20) . Cartilage and SCB from the medial tibial plateau, excluding the joint margins and/or osteophytes, were lasercaptured (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40378/abstract), and RNA was extracted from pooled sections of an individual mouse.
Expression profiling was performed using SurePrint mouse microarray technology (Agilent) at the Ramaciotti Centre for Genomics (Sydney, Australia). Total RNA from cartilage (70 ng) and SCB (100 ng) was labeled and hybridized using an Agilent miRNA microarray system with an miRNA Complete Labeling and Hyb kit, version 3.0 (catalog no. G4859C, release 21). Analysis of mRNA expression in SCB was performed using SurePrint Mouse mRNA Expression V2 Microarray Technology (catalog no. G4852B; Agilent). Total RNA (100 ng) from the SCB samples was labeled and hybridized using a Low Input Quick Amp WT Labeling Kit (Agilent). Insufficient RNA was available from cartilage to allow similar microarray analysis, but selected mRNAs were evaluated by qPCR (see below).
Integrated miRNA:mRNA and functional enrichment analyses. Bioinformatic analysis to identify putative miRNA targets was performed by uploading statistically significant (adjusted P < 0.05) miRNA:mRNA expression data (20) into the MicroRNA Target Filter module within the Ingenuity Pathway Analysis (IPA) application (Qiagen) to generate a network of putative miRNA gene targets directly relevant to OA cartilage. Previous mRNA expression data were generated from a unilateral DMM model at the same 1-week and 6-week time points as used in the present study (20) . Inversely expressed interactions between miRNA and mRNA were selected, and functional enrichment analysis of miRNA targets was performed using ToppGene (21) with a Benjamini-Hochberg false discovery rate-adjusted P value cutoff of <0.05. Gene Ontology (GO) terms and associated P values generated through ToppGene were summarized and visualized using REViGO (22) . Interactive graphs were subsequently generated using Cytoscape software (23) .
Quantitative PCR analysis. Total RNA from cartilage (10 ng) was used for miRNA validation via the miScript miRNA RT qPCR system (Qiagen). Residual cartilage RNA was amplified in 2 rounds using a MessageAmp II aRNA Amplification kit (Ambion). Complementary DNA synthesis of 100 ng of amplified RNA was performed using a QuantiTect Reverse Transcription kit (Qiagen). Quantitative PCR was conducted using Brilliant III SYBR Green (Agilent). Quantitative PCR was conducted using a LightCycler 480 (Roche). Reactions were performed in duplicate with U6 and SNORD61 as internal reference controls for miRNA expression and Atp5b and Rpl10 for mRNA expression (20) .
Statistical analysis. Differences in histopathology scores between groups and between time points were analyzed using nonparametric ranked Kruskal-Wallis analysis, and when significant (P < 0.05) the Mann-Whitney U test (for unpaired data) was performed for between-group comparisons, with Benjamini-Hochberg correction for multiple comparisons (StatSE software; StataCorp).
The microarray data were background corrected using the Normexp method and normalized with cyclic loess, as described elsewhere (18) , using the Bioconductor package Limma version 3.20.9 (24) . Only probes with a 10% greater signal than the negative controls in at least 4 samples were maintained for differential expression analysis. Probes were summarized at the probe level and then at the gene level using the Limma avereps function, with control probes removed. Differential expression was assessed using moderated t-tests from the Limma package. Results were adjusted for multiple testing using the Benjamini-Hochberg method to control for the false discovery rate. The data have been submitted to the GEO data repository (accession no. GSE101574; https://www.ncbi.nlm.nih.gov/geo/).
Quantitative PCR expression was quantified using the comparative C t method. The results were analyzed by nonparametric unpaired Mann-Whitney U test to evaluate differences between group comparisons (GraphPad Prism software, version 7.01). , and F, osteophyte maturity (range 0-3) in the proximal tibias of male wild-type mice at 1 week and 6 weeks following sham surgery (S1 and S6) or destabilization of the medial meniscus (DMM; [D1 and D6]). Each symbol represents an individual mouse; horizontal lines with bars show the mean AE 95% confidence interval (n = 11 mice at each time point in the sham surgery group and n = 9 mice at 1 week and 12 mice at 6 weeks in the DMM group). P values were determined by Mann-Whitney U test with Benjamini-Hochberg correction for multiple comparisons.
RESULTS
Histologic characterization of articular cartilage and SCB. Chondrocyte hypertrophy was significantly increased both at 1 week and at 6 weeks in joints subjected to DMM, but this did not progress with time ( Figure 1A ). There was no change in proteoglycan loss in DMM joints compared with sham-operated joints at 1 week, but significant proteoglycan loss was observed in the DMM group with time and in the DMM versus sham-operated groups at 6 weeks ( Figure 1B) . Similarly, total cartilage structural damage scores did not differ between the DMM and shamoperated groups at 1 week, but scores increased with time in the DMM group and were greater than those in the sham-operated group at 6 weeks ( Figure 1C ).
There was no difference in SCB sclerosis between surgeries at 1 week ( Figure 1D ), but by week 6, there was significant sclerosis in DMM joints compared with shamoperated joints and in DMM joints at 6 weeks compared with DMM joints at 1 week ( Figure 1D ). There was no osteophyte development at 1 week, but at 6 weeks, osteophytes had formed in the DMM joints and were larger and more mature than those in the sham-operated joints, as well as with maturation progressing with time in DMM joints ( Figures 1E and F) .
Expression profiling of SCB tissue. Of the 1,881 miRNAs represented on the microarrays, 490 were detected above background in the SCB samples. Following stringent analysis (18), we did not observe any statistically significant differences in miRNA expression in SCB between DMM and sham surgeries at either 1 week or 6 weeks (data available at the GEO data repository, accession no. GSE101574) (Figures 2A and B) . However, 37 miRNAs were statistically significantly dysregulated with postoperative time in SCB samples (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40378/abstract). As with the miRNA analysis, no statistically significant SCB mRNA dysregulation was identified between DMM and sham surgeries at either time point (GEO data repository GSE101574) (see Supplementary Figure 2 , available at http://onlinelibrary. wiley.com/doi/10.1002/art.40378/abstract), but temporal mRNA expression changes were observed (Supplementary Figure 2 ). These data demonstrate that our microarray approach has the sensitivity to detect miRNA and mRNA dysregulation, if present, in SCB samples from sham versus DMM groups.
Dysregulated miRNA expression in DMM-induced OA cartilage. A total of 438 miRNAs were detected above background in the cartilage samples, 359 (~82%) of which were also coexpressed in SCB, with the remaining 79 miRNAs being exclusively expressed in cartilage (Figure 2E) . In contrast to the SCB, miRNA expression profiling revealed 122 and 74 miRNAs that were significantly differentially expressed (adjusted P < 0.05) in cartilage from DMM mice versus sham-operated mice at 1 and 6 weeks postsurgery, respectively (Supplementary Tables 2 and 3 , available at http://onlinelibrary.wiley.com/doi/10.1002/art. 40378/abstract). Of those, 69 miRNAs were up-regulated and 53 miRNAs were down-regulated at 1 week after surgery in samples from DMM versus sham-operated joints ( Figure 2C ). At 6 weeks, 42 miRNAs were up-regulated, and 32 miRNAs were down-regulated in DMM joints versus sham-operated joints ( Figure 2D ).
Further analysis also demonstrated temporal patterns of differential miRNA expression. Of the 139 miRNAs dysregulated during the 6-week study, 65 and 17 miRNAs were uniquely dysregulated at 1 and 6 weeks, respectively (Figures 3Ai and B) . Additionally, a cohort of 57 dysregulated miRNAs were common to both the 1-week and 6-week time points ( Figure 3B ). Moreover, of the 139 miRNAs dysregulated in cartilage, 110 were found to also be coexpressed in SCB but not differentially regulated. The remaining 29 miRNAs were found to be uniquely expressed and dysregulated in cartilage ( Figure 2F ).
To prioritize miRNA OA candidates from the pool of 139 dysregulated miRNAs, we used a comprehensive multistep filtering approach (Figure 3) . First, dysregulated miRNAs were filtered (based on name and/ or mature sequence homologies) to select those with known human orthologs (71 of 139) (Figure 3Aii ), which were thus more likely to be of relevance to human disease. As described in detail below, further filtering using integrated miRNA:mRNA (target) expression, engagement with pathologic pathways in the OA mouse cartilage (Figure 3Aiii ), and comparison with miRNAs previously described in human end-stage OA cartilage (Figure 3Aiv ), was done. This procedure identified 2 cohorts of dysregulated miRNA OA candidates: group A, which consisted of miRNAs that overlap with human end-stage OA candidates, and group B, which consisted of novel miRNAs not previously described in OA.
Findings of integrated miRNA:mRNA expression analysis. To explore the functional importance of the dysregulated miRNAs with known human orthologs, we performed a bioinformatics-based analysis to identify putative target genes significantly regulated by miRNAs that were differentially expressed in OA cartilage at 1 and 6 weeks post-DMM (Supplementary Tables 4 and 5 , available at http://onlinelibrary.wiley.com/doi/10.1002/art. 40378/abstract). To do this, we used our previous cartilage mRNA expression profiling of DMM-operated wild-type 386 KUNG ET AL Figure 2 . Profiling the expression of microRNAs (miRNAs) in mouse subchondral bone (SCB) and articular cartilage. A and B, Microarray plots displaying average log-expression intensity values and log 2 fold-change for each miRNA expressed in SCB samples obtained at 1 week (A) and 6 weeks (B) from mice subjected to destabilization of the medial meniscus (DMM) or sham surgery. There were no significant changes in miRNA expression in SCB samples from the DMM group versus the sham-operated group. C and D, Volcano plots showing differentially expressed miRNAs with adjusted P values of <0.05 in cartilage obtained at 1 week (C) and 6 weeks (D) from the DMM group versus the sham-operated group. At 1 week, a total of 122 miRNAs were significantly dysregulated (adjusted P < 0.05) in the DMM group versus the sham-operated group (blue plus red symbols). Of those, 69 miRNAs were up-regulated (red) and 53 were down-regulated (blue) in the DMM group versus the sham-operated group. At 6 weeks, a total of 74 miRNAs were significantly dysregulated (adjusted P < 0.05) in the DMM group versus the sham-operated group (blue plus red symbols). Of those, 42 miRNAs were up-regulated (red) and 32 were down-regulated (blue) in the DMM group versus the sham-operated group. Gray symbols represent nonsignificant entities. E and F, Comparison of miRNA expression in SCB and articular cartilage. Of 438 miRNAs detected above background in the cartilage samples (E), 359 were coexpressed in SCB. The remaining 79 miRNAs were exclusively expressed in cartilage. Of 139 miRNAs dysregulated in cartilage (F), 110 were also expressed, but not dysregulated, in SCB. A total of 29 miRNAs were uniquely expressed and dysregulated in cartilage.
CARTILAGE miRNA DYSREGULATION IN OA 387 mice (at the same 1-week and 6-week time points) (20) .
We verified that the current cohort of mice used for miRNA expression analysis displayed comparable expression profiles of key genes (Supplementary Figure 3, available at http://onlinelibrary.wiley.com/doi/10.1002/art. 40378/abstract). We integrated both miRNA and mRNA datasets using the miRNA target prediction module within IPA to , and Venn diagrams comparing dysregulated miRNAs at 1 week and 6 weeks after surgical destabilization of the medial meniscus (DMM) after each of the filtered criteria (B). A, i, Statistically significant miRNAs dysregulated at 1 week and/or 6 weeks post-DMM versus sham surgery (139 miRNAs in total) were filtered based on ii, the existence of their known human orthologs to maximize translational relevance to patients (71 of 139). iii, Expression data for mRNA (target) were integrated alongside those of miRNA in Ingenuity-based target prediction analysis (IPA). A total of 57 miRNAs displayed target mRNA information, which was subsequently used in downstream functional analyses. iv, These 57 miRNAs were compared with miRNA candidates previously identified in human end-stage osteoarthritis (OA) studies (miR cohorts). Twelve miRNAs overlapped with those already described in human end-stage OA (group A), and 45 miRNAs included novel miRNA candidates not previously identified in human OA (group B). adj.p.val = adjusted P value.
388
KUNG ET AL predict or identify experimentally observed target genes. At 1 week post-DMM, IPA miRNA target analysis recognized 46 miRNAs targeting 397 mRNAs, and at 6 weeks, there were 29 miRNAs targeting 510 mRNAs (Supplementary  Tables 4 and 5) . Altogether, mRNA target data were generated for 57 of the 71 differentially expressed miRNAs with known human orthologs across both time points (Figure 3Aiii ). For example, Ptgs2 (Cox2), which was one of the most highly up-regulated genes in DMM cartilage at both 1 week and 6 weeks (20) , was shown to be experimentally regulated by multiple miRNAs in our dataset, including miR-26b-5p, miR-98-5p, miR-15a-5p, and let-7d-5p, all of which were statistically significantly down-regulated in DMM cartilage (Tables 1 and 2 and Supplementary  Tables 4 and 5 ). Similarly, Npr3 may also be regulated by several dysregulated miRNAs, including miR-30c-5p, miR-149-5p, and miR-15a-5p (Tables 1 and 2) , as well as miR-107-3p, miR-10a-5p, and miR-128-3p (Supplementary Tables 4 and 5 ). We also identified other potentially important inverse miRNA-mRNA paired interactions involved in OA pathologic networks, such as miR-26b-5p-Col10a1, miR-224-5p/miR-425-5p-Il11, miR-28-5p/ miR-30c-5p/miR-377-3p-Nt5e, miR-337-3p-Fos, and miR-128-3p-Npy.
Comparison with studies of human end-stage OA. When miRNA candidates identified from 4 independent studies examining human end-stage OA cartilage or chondrocytes (25-28) were compared, there was a striking lack of overlap, with only 6 of 50 miRNAs (miR-342-3p, miR-25, miR-22-3p, miR-23b, miR-26-5p, and miR-30-5p) being common to any of the human studies (Supplementary Figure 4 , available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40378/abstract). In fact, none were common * The predicted and/or experimentally validated mRNA targets of group A dysregulated microRNAs (miRs) that overlap with human end-stage osteoarthritis microRNA candidates are shown. EO = experimentally observed; M = moderate; H = high; acyl-CoA = acylcoenzyme A; EGF = epidermal growth factor; TNF = tumor necrosis factor; AP-1 = activator protein 1.
to all 4 studies, and only 1 miRNA (miR-25) was common to 3 of the studies. In contrast, of the 50 dysregulated human OA miRNAs identified across the 4 studies (25-28), 12 overlapped with those from our current study (group A) (Figure 3Aiv and Supplementary Tables 2 and 3 ). As miR-15a-5p and miR-16-5p are members of the same miRNA family, with highly similar mature sequences and the same seed sequence, these 2 miRNAs were classified as a single candidate of interest. Furthermore, all of these group A miRNAs displayed OA-regulated miRNA-mRNA target interactions (Tables 1 and 2 and Supplementary  Tables 4 and 5 ), for instance, miR-26b-5p-Ptgs2/Col10a1, miR-30c-5p-Nt5e/Npr3, miR-98-5p-Ptgs2/Chsy3/Ngf, miR-149-5p-Npr3/Tnfrsf12a/Dll1/Fosl, miR-337-3p-Fos/ Fgf1, miR-15a-5p-Ptgs2/Npr3, and miR-342-3p-Il11/ Crlf1/Inhba/Pdgfra.
The remaining 45 dysregulated mouse cartilage miRNAs (group B) (Figure 3Aiv ) did not overlap with those identified in the 4 human studies and include novel candidates not previously associated with OA. The most up-regulated were miR-574-5p, miR-31-5p, and miR195a-3p, and the most down-regulated were miR-196b-5p, miR-411-3p, and miR-451a (Supplementary Tables 2 and  3 ). Within this group B, let-7d-5p was an interesting candidate, as Ptgs2 was an experimentally observed target (Supplementary Table 5 ). IPA-generated target filter analysis also revealed Tns1 (tensin 1), a focal adhesion protein, as a potential target of miR-31-5p (Supplementary Table 5 ).
Validation of candidate miRNAs by qPCR. We confirmed prioritized group A and group B miRNA candidate dysregulation by qPCR in additional biologic replicates ( Supplementary Figures 5 and 6 (26, 28, 29) and validating DMM as a model of human OA. Independence of dysregulated miRNA candidate expression from aggrecan breakdown. To temporally position the candidate miRNAs in OA onset and progression, we interrogated the expression of our validated miRNA candidates in mice with an aggrecan mutation that endows resistance to aggrecanase cleavage in the interglobular domain and protection from DMM-induced cartilage proteoglycan loss and subsequent structural damage (Jaffa mice; Acan p.374ALGS?374NVYS) (14) . Interestingly, all the dysregulated candidate miRNAs in wild-type mice were similarly dysregulated in Jaffa mice following DMM (Supplementary Figures 6 and 7 , available at http://online library.wiley.com/doi/10.1002/art.40378/abstract), indicating that the dysregulation occurred independently of aggrecan degradation.
DISCUSSION
We profiled miRNA expression in cartilage and SCB samples from joints of mice with early OA, with the aim of exploring novel disease mechanisms which could underpin new therapeutic strategies. In total, 139 miRNAs were dysregulated in wild-type mouse cartilage during the 6-week development of posttraumatic OA. Interestingly, 122 miRNAs (88%) were found to be dysregulated at 1 week in DMM joints, prior to significant aggrecan or structural degradation, which suggests that miRNA dysregulation could be involved in the initiation of OA pathology and thus represents an ideal window for clinical benefit following posttraumatic injury. Importantly, the use of mice resistant to aggrecan degradation (14) showed that the altered expression of candidate miRNAs was independent of aggrecan cleavage, consistent with their early-disease dysregulation. Taken together, these findings suggest that the differential expression of these cartilage miRNAs occurs not as a result of the inflammation induced by joint injury/surgery (equivalent in sham and DMM), but as a response to increased mechanical stress induced by DMM surgery and initiation of the OA process in the chondrocytes, rather than the downstream consequences of aggrecanolysis.
A previous study on early posttraumatic OA identified a dysregulation of 34 miRNAs in whole joint extracts obtained from mice at 1 week post-DMM (30) . In comparison, we identified 122 dysregulated miRNAs at the same time point, only 4 of which were common to both studies (miR-136-5p, miR-210-3p, miR-214-5p, and miR-379-5p). The lack of commonality and our ability to detect a greater number of aberrantly expressed miRNAs was most likely a result of the targeted isolation of cartilage and SCB in our studies, in contrast to the use of whole tissue extracts, which may mask important cartilage-specific pathologic changes.
We compared our dataset with current miRNA datasets from human OA studies (25) (26) (27) (28) . As the mouse OA model coincides with early-stage cartilage degeneration and the human samples are from end-stage disease, miRNAs common to both groups are likely to be important throughout the OA process. The striking lack of overlap between the human studies emphasizes the patient and pathologic variability of available clinical samples of OA cartilage, which makes interpreting the significance of the human OA miRNAs and prioritizing miRNAs for further functional studies and then therapeutic development difficult. Our studies, which interrogated genetically matched samples from a clinically reproducible OA model, overcome this problem and provide confidence that our overlapping, confirmed 7 miRNA candidates (group A) are representative of both early and late-stage OA. Importantly, when we conducted paired target analysis, all group A miRNA candidates showed the corresponding cartilage expression changes of predicted or experimentally determined mRNA targets, compatible with the direction of change in miRNA expression (Figure 3 and Tables 1 and  2 ). Thus, miR-15a/16-5p, miR-26b-5p, miR-30c-5p, miR-98-5p, miR-149-5p, miR-210-3p, and miR-342-3p offer important potential targets in a critical and wide therapeutic window. These are discussed in more detail below.
MicroRNA-15 and miR-16 form a family of related small noncoding RNAs clustered within 0.5 kb in the human genome. Studies have shown miR-16 to be differentially up-regulated in human OA cartilage and plasma samples (26, 31, 32) . SMAD3, which plays important roles in cartilage development and inflammation, was identified as a target gene of miR-16 in human chondrocytes (31) . Furthermore, Ptgs2 and Npr3, both of which are highly up-regulated in OA cartilage, were identified as experimentally validated targets of miR-15/16 seed sequences (Table 2) , and both genes are known to play important roles in cartilage homeostasis and pathologic processes of OA (20, 33) . While the regulation of miR-15/ 16 cluster expression has not been well studied, there is some evidence that miR-16 is mechanosensitive, and its regulation is dependent on the direction of mechanical stretch in mouse diaphragm muscles (34) .
It was striking that Ptgs2 (Cox2) was identified as a common target between several dysregulated candidate miRNAs in our study (miR-98-5p, miR-26b-5p, miR-15a-5p and let-7d-5p) ( Tables 1 and 2 and Supplementary  Tables 4 and 5 ). Ptgs2 is involved in the biosynthesis of prostaglandin E 2 , a major catabolic and inflammatory mediator of cartilage degradation. With varying degrees of effectiveness and with controversy surrounding the safe clinical use of cyclooxygenase 2 (Cox-2) inhibitors for the management of OA, the importance of Cox-2 inhibition remains to be determined (35, 36) . Nevertheless, the potential coregulation of Ptgs2 by several OA-dysregulated miRNAs warrants further preclinical studies investigating the importance of these miRNAs to OA pathology and their potential as alternative, more effective therapeutic targets.
Members of the miR-30 family have been shown to be either differentially up-or down-regulated in human OA (26, 28, 37) . Specifically, we demonstrated miR-30c-5p to be significantly down-regulated in early DMM cartilage, and IPA target analysis revealed Npr3 as an experimentally validated target of miR-30c-5p (Table 1) . Npr3 (C-type natriuretic peptide) signaling is important in maintaining cartilage function, inducing catabolic responses via MEK/ERK signaling, and stimulating anabolic activities via ERK-1/2 in an attempt to maintain homeostatic function (33) . Npr3 not only has interesting OA-related activities, but it is also potentially targeted by miR-15/16 and miR-149, which suggests that the miRNAs have shared regulatory networks.
MicroRNA-98-5p has been recognized as a mechanosensitive miRNA, with its expression responsive to mechanical stretch in mouse diaphragm muscles and with gene targets associated with extracellular matrix (ECM) and transforming growth factor b (TGFb) pathways (34) . MicroRNA-98-5p has also been linked to OA inflammatory pathways by modulating the IL-1b-mediated production of tumor necrosis factor (25) . Intriguingly, the down-regulation of miR-98-5p has been associated with an increase in apoptosis in human chondrocytes, and exogenous injection of a miR-98 mimic into an OA rat model demonstrated promising therapeutic benefit (38) . Conversely, another rat OA study revealed contradictory findings of miR-98 overexpression, leading to detrimental effects on chondrocyte apoptosis and cartilage integrity (39) . More studies are needed to conclusively determine the functional role of miR-98. Similar OA inflammatory roles have also been implicated for miR-149-5p (40) and miR-210-3p (41) . Consistent with our findings, miR-210-3p was decreased in OA in rats, and its expression was regulated by lipopolysaccharideinduced inflammation (42) . Overexpression of miR-210-3p in rats with OA decreased inflammation by inhibiting the NF-jB pathway, which reduced cytokine production, leading to antiinflammatory and antiapoptotic effects (42) . The role of miR-342 in cartilage is unknown. However, our miRNA-mRNA target prediction analysis identified several OA-relevant predicted targets, including Bmp7, Inhba, and Il11 (Table 2) .
Collectively, the above data confirm the validity of our approach for discovering and prioritizing highpriority candidate OA miRNAs for comprehensive functional and therapeutic assessments. The remaining 45 miRNAs in group B have not previously been associated with OA. Using PCR, we confirmed miR-574-5p, miR-31-5p, and let-7d-5p to be novel OA-dysregulated miRNA candidates (Supplementary Figure 6) . No information could be found alluding to let-7d-5p function in cartilage biology. On the other hand, miR-574 was up-regulated during the early phases of mesenchymal stem cell (MSC) chondrogenic differentiation (43) . Furthermore, overexpression of miR-574 resulted in inhibition of aggrecan and type II collagen expression via a retinoid X receptor a (RXRa)-SOX9 feedback mechanism (43) . MicroRNA-574 has also been shown to target members of the b-catenin/Wnt signaling pathway (44), which we know to be pathologically dysregulated in OA (20) . MicroRNA-31-5p was also shown to be down-regulated in MSCs derived from degraded cartilage as compared with those from apparently healthy cartilage obtained from the same donor (45) . MicroRNA-31-5p was also predicted computationally to be a potential regulator of TGFb3/bone morphogenetic protein 2 (BMP-2)-driven processes during chondrogenesis of MSCs (46) . Nevertheless, the importance of miR-31-5p, miR-574-5p, and let-7d-5p in the context of cartilage/chondrocyte function and OA pathology remains to be explored.
To gain a holistic insight into the functional processes significantly affected by all OA-dysregulated miRNA-mRNA interactions during early OA initiation (1-week DMM, groups A and B), functional enrichment analysis of mRNAs alone (20) and miRNA targets was conducted (Supplementary Figure 8 , available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40378/abstract, and Figure 4 , respectively). Significant biologic processes disrupted during early OA were identified using ToppGene (21) and then clustered using REViGO (22) . The majority of biologic clusters, for example, regulation of the MAPK cascade, cell migration, cell development, cell adhesion, ECM organization, and cell growth, were common to both datasets (mRNAs alone and miRNA-regulated mRNA targets). Interestingly however, response to mechanical stimuli and apoptosis-associated biologic processes appeared to be specifically enriched in the miRNAdysregulated mRNA target dataset (Figure 4 ). Moreover, with cartilage structural integrity and ECM turnover being central to OA pathology, we used the Matrisome annotation tool to examine how miRNA changes may influence key components of the ECM (47, 48) . Key ECM genes at the total mRNA and miRNA-dysregulated mRNA target level were identified and annotated (Supplementary Figure 9 , available at http://onlinelibrary.wiley.com/doi/10.1002/ art.40378/abstract), demonstrating that the dysregulated miRNAs have the potential to influence not only OApertinent cellular processes, but also both core ECM structural and homeostatic factors.
We also profiled miRNA and mRNA expression in the adjoining SCB tissue to better characterize the relationship between the two tissues. However, we did not detect statistically significant dysregulation of miRNAs or mRNA in SCB tissue from DMM versus shamoperated mice. Our findings contrast with 2 studies that identified miRNA dysregulation in SCB tissue from patients with end-stage OA (25, 49) . The obvious study discrepancies (species, model, and stage of disease progression) may account for the lack of commonality between our data sets. Patients with end-stage OA Figure 4 . Gene Ontology (GO) biologic processes associated with dysregulated microRNA (miRNA) targets during early osteoarthritis (OA) initiation. Functional enrichment analysis using ToppGene was performed on putative miRNA targets to highlight the biologic processes that were most significantly affected by dysregulated miRNA-mRNA interactions during early OA initiation. GO terms (adjusted P < 0.05) were summarized and visualized using REViGO and Cytoscape. Boxes represent the top clusters of biologic processes significantly influenced by dysregulated miRNA targets. Intensity of the node color indicates significance according to adjusted P values, with highly significant GO terms in darkest red. Highly similar GO terms are linked by lines, where the line width indicates the degree of similarity. ECM = extracellular matrix. exhibit substantial changes of the SCB affected by years of progressive OA. In comparison, our studies were conducted over a 6-week time period and thus recapitulate a mild early pathology. Investigating later time points after DMM would confirm whether miRNA changes occur with advanced pathology; however, therapeutic intervention at such a late stage of disease would be limited from a disease-modifying prospective. Another unavoidable limitation is that a proportion of extracted RNA may arise from cells in the bone marrow, which could obscure any changes in the bone lining cells, activated osteoblasts, and osteocytes, that are likely most affected by and responsible for the pathologic changes of OA in bone. Importantly however, we demonstrated that although~80% of the total number of miRNAs expressed and dysregulated in cartilage were also found in SCB tissue, none of these were significantly differentially regulated in OA SCB.
Collectively, this supports the notion that OA is associated with cartilage-specific regulation of commonly expressed miRNAs, rather than the regulation of cartilage-specific miRNAs. Taken together, our findings provide a robust platform and validated pool of high-priority cartilage-regulated miRNAs that act as potential regulators of early OA initiation and progression.
